Centessa Pharmaceuticals (CNTA) Common Equity (2022 - 2025)
Historic Common Equity for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $301.6 million.
- Centessa Pharmaceuticals' Common Equity fell 3958.09% to $301.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $301.6 million, marking a year-over-year decrease of 3958.09%. This contributed to the annual value of $401.5 million for FY2024, which is 6997.05% up from last year.
- Per Centessa Pharmaceuticals' latest filing, its Common Equity stood at $301.6 million for Q3 2025, which was down 3958.09% from $344.9 million recorded in Q2 2025.
- In the past 5 years, Centessa Pharmaceuticals' Common Equity registered a high of $499.1 million during Q3 2024, and its lowest value of $215.2 million during Q1 2024.
- Over the past 4 years, Centessa Pharmaceuticals' median Common Equity value was $336.2 million (recorded in 2022), while the average stood at $340.7 million.
- As far as peak fluctuations go, Centessa Pharmaceuticals' Common Equity skyrocketed by 9242.72% in 2024, and later crashed by 3958.09% in 2025.
- Over the past 4 years, Centessa Pharmaceuticals' Common Equity (Quarter) stood at $336.2 million in 2022, then decreased by 29.72% to $236.2 million in 2023, then skyrocketed by 69.97% to $401.5 million in 2024, then fell by 24.9% to $301.6 million in 2025.
- Its Common Equity was $301.6 million in Q3 2025, compared to $344.9 million in Q2 2025 and $386.2 million in Q1 2025.